Sales Halted in Biotech Drug Because of Link to a Death
Sales of drug Tysabri for treatment of multiple sclerosis are abruptly suspended after product is linked to fatal neurological disease called progressive multifocal leukoencephalopathy, or PML; drug, jointly marked by Biogen Idec and Elan, was approved by Food and Drug Administration three months ago under procedure designed to speed introduction of drugs for serious diseases; Biogen's chief executive James C Mullen comments; Biogen's stock loses 43 percent of market value, plunging $28.63 to $38.65; graph; photo (M)